Key Points
- Director William Phd Link sold 12,500 Tarsus Pharmaceuticals shares at an average price of $78.38, generating $979,750. The Rule 10b5-1 transaction reduced his holdings by 11.68% to 94,487 shares.
- Tarsus reported a quarterly loss of $0.43 per share, missing analyst expectations of a $0.19 loss, though revenue of $173.91 million exceeded estimates. Analysts forecast a full-year loss of approximately $2.40 per share.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $94 price target versus the stock’s $79.03 opening price; institutional investors own 90.01% of the company.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) Director William Phd Link sold 12,500 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total transaction of $979,750.00. Following the sale, the director owned 94,487 shares in the company, valued at $7,405,891.06. This represents a 11.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tarsus Pharmaceuticals Stock Performance
Shares of NASDAQ:TARS opened at $79.03 on Friday. Tarsus Pharmaceuticals, Inc. has a 1 year low of $51.57 and a 1 year high of $91.53. The stock has a market capitalization of $3.47 billion, a price-to-earnings ratio of -72.50 and a beta of 0.54. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. The company's 50 day simple moving average is $69.02 and its 200 day simple moving average is $66.73.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The business had revenue of $173.91 million for the quarter, compared to the consensus estimate of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. As a group, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.4 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research report on Friday, July 17th. Jefferies Financial Group lifted their target price on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a "buy" rating in a research report on Tuesday, September 8th. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Barclays assumed coverage on Tarsus Pharmaceuticals in a research note on Wednesday. They set an "overweight" rating and a $110.00 target price for the company. Finally, Mizuho dropped their target price on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating for the company in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Tarsus Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $94.00.
Read Our Latest Stock Analysis on Tarsus Pharmaceuticals
Institutional Trading of Tarsus Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Engineers Gate Manager LP increased its holdings in shares of Tarsus Pharmaceuticals by 66.5% during the second quarter. Engineers Gate Manager LP now owns 4,755 shares of the company's stock worth $299,000 after buying an additional 1,900 shares in the last quarter. Squarepoint Ops LLC lifted its stake in shares of Tarsus Pharmaceuticals by 22.7% in the 2nd quarter. Squarepoint Ops LLC now owns 295,824 shares of the company's stock valued at $18,619,000 after acquiring an additional 54,791 shares during the last quarter. Nykredit A S acquired a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $106,000. Pale Fire Capital SE boosted its holdings in shares of Tarsus Pharmaceuticals by 73.4% during the 2nd quarter. Pale Fire Capital SE now owns 9,802 shares of the company's stock valued at $617,000 after acquiring an additional 4,150 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its holdings in shares of Tarsus Pharmaceuticals by 295.0% during the 2nd quarter. Hsbc Holdings PLC now owns 38,090 shares of the company's stock valued at $2,429,000 after acquiring an additional 28,447 shares in the last quarter. Institutional investors own 90.01% of the company's stock.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye conditions with significant unmet medical needs. The company's lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, a common eyelid disorder associated with an infestation of Demodex mites.
XDEMVY is designed to target and eliminate Demodex mites, addressing an underlying cause of the disease rather than only managing its symptoms.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
